Compare Johnson & Johnson (JNJ) vs Vanguard Mega Cap Growth ETF (MGK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Vanguard Mega Cap Growth ETF — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while Vanguard Mega Cap Growth ETF trades at $94.43 (market cap $33.70B). The key difference: Johnson & Johnson is far larger — about 18.3× Vanguard Mega Cap Growth ETF's market cap, and Johnson & Johnson pays a 2.09% dividend while Vanguard Mega Cap Growth ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Vanguard Mega Cap Growth ETF for 45 Days on average.
| JNJ | MGK | |
|---|---|---|
Market Cap | $618.09B | $33.70B |
Volume | 6,050,983 | 1,362,010 |
Sector | Health | Broad Market / Factor |
52-Week High | $278.43 | $95.11 |
52-Week Low | $186.00 | $70.70 |
Typical Hold Time | 129 Days | 45 Days |
Enterprise Value | $646.37B | — |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
MGK, the Vanguard Morningstar Mega Cap Growth ETF, trades at $94.42, down 0.53% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF provides exposure to large-cap U.S. growth stocks like Nvidia and Apple, with a low expense ratio of 0.05% (Vanguard, 2026-07-18). Recent news highlights its strong five-year returns and suitability for long-term growth investors.
The outlook for MGK is positive, driven by its concentrated mega-cap growth holdings and cost efficiency, though risks include tech sector volatility and market concentration. Analyst sentiment is favorable, emphasizing its role in growth portfolios for investors seeking higher returns with manageable risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Vanguard Mega Cap Growth ETF
MGK is an ETF that seeks to track the performance of the CRSP US Mega Cap Growth Index. It provides a low-cost, diversified exposure to the largest growth companies in the U.S. stock market. The fund is composed of mega-cap stocks that exhibit key growth factors, including high expected long-term earnings growth, high historical sales and earnings growth, and high return on assets. MGK is typically used by investors seeking long-term capital appreciation from market-leading firms.
Read more on MGK →
